Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $18.75.

Several brokerages have recently issued reports on LXEO. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. decreased their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Finally, Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Insider Activity

In other news, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the sale, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This represents a 21.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the transaction, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 62,204 shares of company stock worth $280,089 over the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. Bank of America Corp DE grew its holdings in Lexeo Therapeutics by 6.1% during the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after purchasing an additional 1,626 shares during the last quarter. California State Teachers Retirement System raised its position in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the period. Intech Investment Management LLC raised its position in Lexeo Therapeutics by 19.5% in the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after purchasing an additional 2,317 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Lexeo Therapeutics by 25.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock worth $118,000 after purchasing an additional 2,427 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $4.81 on Monday. The stock has a 50 day moving average of $4.63 and a 200 day moving average of $5.71. Lexeo Therapeutics has a 12 month low of $3.99 and a 12 month high of $10.99. The firm has a market cap of $377.68 million, a PE ratio of -3.32 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, equities research analysts forecast that Lexeo Therapeutics will post -1.18 earnings per share for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.